ADCT-242 / ADC Therapeutics - LARVOL DELTA

Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small lung cancer models (AACR 2025) - "Furthermore, the anti-tumor activity of ADCT-242 in combination with olaparib, bevacizumab or platinum-based drug, such as cisplatin, was investigated in vitro and in vivo in Claudin-6 positive ovarian models. In conclusion, the data presented provide preclinical evidence for superior anti-tumor activity of ADCT-242 vs AB3-7-MMAE in an ovarian CDX model. Furthermore, ADCT-242 was associated with strong anti-tumor activity in NSCLC PDX models, whereas synergistic combination activity with approved drugs such as the PARP inhibitor olaparib, was demonstrated."

Preclinical • Endometrial Cancer • Gastric Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Testicular Cancer • CLDN6

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 (PRNewswire) - "Data from the preclinical investigation of ADCT-242, a novel exatecan-based ADC targeting CLDN6, were presented in an oral presentation titled, 'Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small lung cancer models'....ADCT-242 demonstrated potent anti-tumor activity in vivo in PA-1 and OVCAR-3 xenograft models with medium CLDN6 expression; CLDN6-dependent anti-tumor activity of ADCT-242 was observed in lung patient-derived tumor models; ADCT-242 was tolerated in mice or cynomolgus monkeys at doses up to 150 mg/kg or 40 mg/kg, respectively, indicative of a good therapeutic index."

Preclinical • Non Small Cell Lung Cancer • Ovarian Cancer

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PRNewswire) - "ADC Therapeutics SA...announced abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025....Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models. Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations."

Preclinical • Non Small Cell Lung Cancer • Ovarian Cancer • Prostate Cancer